Our results have demonstrated that ATRA treatment effectively increased the proportion of Tregs in SSc CD4+ T cells by downregulating the methylation levels of the FOXP3 promoter region and subsequently activating and enhancing FOXP3 expression. The gene discussed is FOXP3; the disease is systemic sclerosis.